FDA allows Philip Morris to market Zyn as less harmful than cigarettes

Key Facts

In a move that underscores the market shift toward reduced-risk alternatives, the U.S. Food and Drug Administration (FDA) has allowed Philip Morris International (PM) to market 20 Zyn nicotine pouch products with a modified-risk claim that switching from cigarettes lowers the risk of several smoking-related diseases. The decision is based on evidence showing Zyn pouches significantly reduce exposure to harmful chemicals compared to traditional cigarettes.

PM shares closed at $182.87 on June 29, after trading between $179.65 and $183.30. The approval comes as the tobacco industry pivots toward nicotine alternatives amid declining cigarette sales globally. Zyn pouches are one of Philip Morris's fastest-growing product lines, strengthening its competitive position in the reduced-risk nicotine market.

On the technical front, the $179.65 session low offers potential support, while $183.30 serves as near-term resistance. Investors will focus on second-quarter earnings to gauge the impact of this regulatory approval on sales. Regulatory developments in other markets also remain in focus, as the FDA's decision could pave the way for similar claims.